tbuckley/cabot-search huggingface dataset:
Philip Milton Kollitsis
Authors: John Skipper, Christos Eliades
Journal: BMJ (2019)

Philip Milton Kollitsis was the consultant ear, nose, and throat surgeon at the Princess Mary’s Hospital at RAF Akrotiri in Cyprus from 1996 until its closure in 2012. He was also in private practice in Nicosia. He had a keen interest in aviation and held the RAF certificate in aviation medicine. He learned to fly at Akrotiri, gained a private pilot’ s licence, and owned a light aircraft for several years. He was always good company and enjoyed …
Recurrent inflammatory disease caused by a heterozygous mutation in CD48
Authors: Benjamin Volkmer, Raquel Planas, Emanuel Gossweiler, Anna Lünemann, Lennart Opitz, Andrea Mauracher, Ursina Nüesch, Tenzin Gayden, Daniela Kaiser, Barbara Drexel, Claudia Dumrese, Nada Jabado, Stefano Vavassori, Jana Pachlopnik Schmid
Journal: Journal of Allergy and Clinical Immunology (2019)
Optimal Combination of Compression Rate and Depth During Cardiopulmonary Resuscitation for Functionally Favorable Survival
Authors: Sue Duval, Paul E. Pepe, Tom P. Aufderheide, Jeffrey M. Goodloe, Guillaume Debaty, José Labarère, Atsushi Sugiyama, Demetris Yannopoulos
Journal: JAMA Cardiology (2019)

Previous studies of basic cardiopulmonary resuscitation (CPR) indicate that both chest compression rate (CCR) and chest compression depth (CCD) each are associated with survival probability after out-of-hospital cardiac arrest. However, an optimal CCR-CCD combination has yet to be identified, particularly with respect to age, sex, presenting cardiac rhythm, and CPR adjunct use.To identify an ideal CCR-CCD combination associated with the highest probability of functionally favorable survival and to assess whether this combination varies with respect to age, sex, presenting cardiac rhythm, or CPR adjunct use.This cohort study used data collected between June 2007 and November 2009 from a National Institutes of Health (NIH) clinical trials network registry of out-of-hospital and in-hospital emergency care provided by 9-1-1 system agencies participating in the network across the United States and Canada (n = 150). The study sample included 3643 patients who had out-of-hospital cardiac arrest and for whom CCR and CCD had been simultaneously recorded during an NIH clinical trial of a CPR adjunct. Subgroup analyses included evaluations according to age, sex, presenting cardiac rhythm, and application of a CPR adjunct. Data analysis was performed from September to November 2018.Standard out-of-hospital cardiac arrest interventions compliant with the concurrent American Heart Association guidelines as well as use of the CPR adjunct device in half of the patients.The optimal combination of CCR-CCD associated with functionally favorable survival (modified Rankin scale ≤3) overall and by age, sex, presenting cardiac rhythm, and CPR adjunct use.Of 3643 patients, 2346 (64.4%) were men; the mean (SD) age was 67.5 (15.7) years. The identified optimal CCR-CCD for all patients was 107 compressions per minute and a depth of 4.7 cm. When CPR was performed within 20% of this value, survival probability was significantly higher (6.0% vs 4.3% outside that range; odds ratio, 1.44; 95% CI, 1.07-1.94; P = .02). The optimal CCR-CCD combination remained similar regardless of age, sex, presenting cardiac rhythm, or CPR adjunct use. The identified optimal CCR-CCD was associated with significantly higher probabilities of survival when the CPR device was used compared with standard CPR (odds ratio, 1.90; 95% CI, 1.06-3.38; P = .03), and the device's effectiveness was dependent on being near the target CCR-CCD combination.The findings suggest that the combination of 107 compressions per minute and a depth of 4.7 cm is associated with significantly improved outcomes for out-of-hospital cardiac arrest. The results merit further investigation and prospective validation.
Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial
Authors: E. Antonio Chiocca, John S. Yu, Rimas V. Lukas, Isaac H. Solomon, Keith L. Ligon, Hiroshi Nakashima, Daniel A. Triggs, David A. Reardon, Patrick Wen, Brittany M. Stopa, Ajay Naik, Jeremy Rudnick, Jethro L. Hu, Priya Kumthekar, Bakhtiar Yamini, Jill Y. Buck, Nathan Demars, John A. Barrett, Arnold B. Gelb, John Zhou, Francois Lebel, Laurence J. N. Cooper
Journal: Science Translational Medicine (2019)

Human interleukin-12 (hIL-12) is a cytokine with anticancer activity, but its systemic application is limited by toxic inflammatory responses. We assessed the safety and biological effects of an hIL-12 gene, transcriptionally regulated by an oral activator. A multicenter phase 1 dose-escalation trial (NCT02026271) treated 31 patients undergoing resection of recurrent high-grade glioma. Resection cavity walls were injected (day 0) with a fixed dose of the hIL-12 vector (Ad-RTS-hIL-12). The oral activator for hIL-12, veledimex (VDX), was administered preoperatively (assaying blood-brain barrier penetration) and postoperatively (measuring hIL-12 transcriptional regulation). Cohorts received 10 to 40 mg of VDX before and after Ad-RTS-hIL-12. Dose-related increases in VDX, IL-12, and interferon-γ (IFN-γ) were observed in peripheral blood, with about 40% VDX tumor penetration. Frequency and severity of adverse events, including cytokine release syndrome, correlated with VDX dose, reversing promptly upon discontinuation. VDX (20 mg) had superior drug compliance and 12.7 months median overall survival (mOS) at mean follow-up of 13.1 months. Concurrent corticosteroids negatively affected survival: In patients cumulatively receiving >20 mg versus ≤20 mg of dexamethasone (days 0 to 14), mOS was 6.4 and 16.7 months, respectively, in all patients and 6.4 and 17.8 months, respectively, in the 20-mg VDX cohort. Re-resection in five of five patients with suspected recurrence after Ad-RTS-hIL-12 revealed mostly pseudoprogression with increased tumor-infiltrating lymphocytes producing IFN-γ and programmed cell death protein 1 (PD-1). These inflammatory infiltrates support an immunological antitumor effect of hIL-12. This phase 1 trial showed acceptable tolerability of regulated hIL-12 with encouraging preliminary results.
A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Authors: Yuqin Song, Jianqiu Wu, Xinchuan Chen, Tongyu Lin, Junning Cao, Yanyan Liu, Yaozhong Zhao, Jie Jin, Haiwen Huang, Jianda Hu, Jun Luo, Liling Zhang, Hongwei Xue, Qingyuan Zhang, Weiwei Wang, Chunxia Chen, Jifeng Feng, Jun Zhu
Journal: Clinical Cancer Research (2019)

For classical Hodgkin lymphoma (cHL), programmed death-l (PD-1) is a well-recognized attractive target. This multicenter, single-arm, phase II study evaluated the efficacy and safety of camrelizumab, a humanized high-affinity IgG4 mAb against PD-1, in Chinese patients with relapsed or refractory cHL.Patients who had failed to achieve a remission or experienced progression after autologous stem cell transplantation or had received at least two lines of systemic chemotherapies were given camrelizumab 200 mg every 2 weeks. The primary endpoint was objective response rate per independent review committee (IRC) assessment. This study is registered with ClinicalTrials.gov (NCT03155425).Between June 9, 2017 and September 18, 2017, 75 patients were enrolled and treated. At a median follow-up of 12.9 months, 57 of 75 (76.0%; 95% CI, 64.7-85.1) patients achieved an IRC-assessed objective response, including 21 (28.0%) and 36 (48.0%) patients who had complete and partial remission, respectively. Median duration of response was not reached (range, 0.0+-12.8+ months). Treatment-related adverse events (AE) occurred in all patients. The most common ones included cutaneous reactive capillary endothelial proliferation (97.3%, 73/75) and pyrexia (42.7%, 32/75). Grade 3 or 4 treatment-related AEs occurred in 20 patients (26.7%); the most common AE was decreased white blood cell count (4.0%, 3/75). There were no grade 5 treatment-related AEs.Camrelizumab demonstrated a high response rate, durable response and controllable safety in Chinese patients with relapsed or refractory cHL, becoming a new safe and effective treatment option in this setting.
Defining the Diversity and Specificity of Neoantigen-Specific T Cells in Chronic Lymphocytic Leukemia
Authors: Zhuting Hu, Jing Sun, Jintaek Kim, Annabelle Jacinta Anandappa, Donna Leet, Louise Williams, David J Bozym, Christina Chen, Wandi Zhang, Diana Tabbaa, Pavan Bachireddy, Sachet Shukla, Scott Steelman, Derin Keskin, Catherine J. Wu
Journal: Blood (2017)
Understanding patient advance directives status in a community oncology practice using an electronic patient-reported outcomes (ePRO) system.
Authors: Joanne S. Buzaglo, Karen E Skinner, Edward Stepanski, Cynthia Tankersley, Lee S. Schwartzberg
Journal: Journal of Clinical Oncology (2019)

e23181 Background: The National Comprehensive Cancer Network and the American Society of Clinical Oncology recommend that providers encourage early advance care planning with their patients 1 ; yet, many cancer patients do not have advance directives (ADs). A potential reason for low AD rates is inadequate communication between the provider and patient. To address this gap, we developed an outpatient clinic AD initiative for any stage cancer patients via an ePRO system. The AD module was designed to ensure that patients are aware of ADs and to assess whether or not the patient had ADs, specifically a Living Will and/or a durable power of attorney. The study purpose was to assess patient AD status at the patient’s initial visit to an oncology clinic. Methods: This study used a retrospective, observational design that involved use of PRO and clinical data collected via the Patient Care Monitor™ (PCM), a web-based ePRO system linked to electronic medical record data. All data used in this study were collected as part of routine clinical care. All patients at an initial visit to an oncology clinic completed the PCM survey, including the AD module, via a handheld e-tablet. Results: Overall, 9,682 patients completed the AD module (mean age 63; 31% male/69% female; 58% married; 62% White, 35% Black). Cancer type was known for 75% of all patients (29% breast, 11% hematologic, 7% lung, 7% colorectal, 3% prostate, 17% other types). One third of all patients (33%) reported having an AD at the time of the initial visit to the oncology clinic, specifically 24% indicated having a Living Will and 9% a durable power of attorney. The remaining two-thirds (67%) indicated either NOT having an AD (56%) or not knowing if they had an AD (11%). Patients with ADs were more likely to be older ( M=68 v. 60 yrs), male (38% v 31%), White (41% v 20% Black) and married/partnered (35% v 29%); ps &lt;.0001. Conclusions: This study demonstrates that the majority of patients do not have ADs at the time of an initial visit to a community-based oncology practice. Using an ePRO system can be an innovative and efficient way to identify unmet needs of patients and link them to resources for developing advance directives. 1 Brown AJ, Shen MJ, Urbauer D, et al. Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients. Gynecol Oncol. Sep 2016;142(3):525-530.
Abstract 9794: Preoperative Iodine-123 MIBG Scintigraphy Imaging as an Excellent Predictor of Left Ventricular Reverse Remodeling During Ventricular Assist Device Therapy
Authors: Teruhiko Imamura, Koichiro Kinugawa, Daisuke Nitta, Masaru Hatano, Osamu Kinoshita, Kan Nawata, Minoru Ono
Journal: Circulation (2015)

Introduction: Although left ventricular reverse remodeling (LVRR) is accompanied by better clinical course during ventricular assist device (VAD) treatment, its preoperative prediction remains uncertain. 123I-metaiodobenzylguanidine (123I-MIBG) is a recently-developed analog of guanethidine, used either to stratify heart failure (HF) or to predict HF patient prognosis by assessing visualized cardiac sympathetic innervation. Hypothesis: Preoperative 123I-MIBG may be useful to predict LVRR during VAD support. Methods: We enrolled 27 HF patients due to dilated cardiomyopathy, who had received 123I-MIBG scintigraphy before the implantation of VAD and been followed at our institute at 2010-14. We investigated whether preoperative 123I-MIBG data were useful to predict postoperative LVRR defined as LV ejection fraction ≥35% at post-VAD 6 months. Results: Among preoperative variables including 123I-MIBG data, washout rate (WR) ≤39% was an only significant independent predictor of postoperative LVRR by uni/multivariate logistic regression analyses (p=0.036 and odds ratio 14.45). Those with LVRR had better exercise capacity including higher peak oxygen consumption at cardiopulmonary exercise test and longer 6 minutes’ walk distances, and more frequent opening of native aortic valve accompanied by lower plasma level of B-type natriuretic peptide at post-VAD 6 months (p&lt;0.05 for all), although their daily dose of β-blocker was comparable with those without LVRR during the study period. All 2 patients who achieved explantation of VAD had experienced LVRR. Conclusions: Preoperative lower WR in 123I-MIBG was a novel predictor of LVRR during VAD support.
Intensity modulation of chemoimmunotherapy for late stages of liver carcinoma.
Authors: Baofa Yu, ZhenLu Ma, Changjiang Guan, Wei Han, Yebin Che, Qiang Fu
Journal: Journal of Clinical Oncology (2012)

e14716 Background: Provenge (Dendreon Co.) is an autologous cellular vaccine and represents a significant milestone for cancer immunotherapy and generates renewed interest in the field. Chemoimmunotherapy as a highly attractive way for cancer treatment has been studied over years but this is not generated a specific powerful immunotherapy yet. Intensity Modulation of Chemoimmunotherapy (IMCIT) is similarly with Provenge function and plays in kill tumor cells and induces patient’s own immunological effect against micro size cancers more than just Introtumoral Chemotherapy(ITCT) alone. Methods: Introtumoral injection of IMCIT into late stages of liver Cancer (447 cases) which is a proprietary therapeutic regimen composed of three components for intensity modulation of chemoimmunotherapy, i.e., an oxidant, a cytotoxic drug and a hapten. Results: After intratumoral injection, coagulate tumor mass for sustained drug release and drug kills tumor cells, a small molecule hapten binds to these antigens and other large carriers for intensity modulation, then autologous tumor antigens released from the dead tumor cells and trigger immune response as a self-vaccination to further boost systemic humoral and cellular immunity for suppression and eradication of tumor recurrence. For single liver tumor, 6 months survival rate for IMCIT 63.03% and ITCT 36.17%(p&lt;0.01), 12 months survival rate for IMCIT 32.77% and ITCT 21.28% (P.0.05);for mutable liver tumors, 6 months survival rate for IMCIT 54.44% and ITCT 20.93%(p&lt;0.01),12 months survival rate for IMCIT 21.11% and ITCT 6.98%(p&lt;0.05). Therefore, more importantly, IMCIT provides a new option for cancer treatment by integrating local chemotherapeutic effect with systemic anti-tumor immunity; cell death induced by chemotherapeutic drugs is a priming event and allows the injected tumor act as its own vaccine. Conclusions: Introtumoral injection of IMCIT is a safe, aggressive and cost-effective clinical treatment for solid tumors. IMCIT displays the following advantages: clinically effective for single and multiple masses liver cancer and minimal side effects and better quality of life; simple and cost-effective treatment and strong intellectual property position..
Enhanced mGlu5 Signaling in Excitatory Neurons Promotes Rapid Antidepressant Effects via AMPA Receptor Activation
Authors: Amrei Holz, Felix Mülsch, Martin K. Schwarz, Michael Hollmann, Mate D. Döbrössy, Volker A. Coenen, Marlene Bartos, Claus Normann, Knut Biber, Dietrich van Calker, Tsvetan Serchov
Journal: Neuron (2019)
Anti-EGFR antibody conjugated thiol chitosan-layered gold nanoshells for dual-modal imaging-guided cancer combination therapy
Authors: Panchanathan Manivasagan, Van Tu Nguyen, Seung Won Jun, Giang Hoang, Sudip Mondal, Hyehyun Kim, Vu Hoang Minh Doan, Jeehyun Kim, Chang-Seok Kim, Junghwan Oh
Journal: Journal of Controlled Release (2019)
A Randomized Noninferiority Trial of Wearing Adjustable Glasses versus Standard and Ready-made Spectacles among Chinese Schoolchildren
Authors: Congyao Y. Wang, Guoshan Zhang, Bobby Tang, Ling Jin, Wenyong Huang, Xiuqin Wang, Tingting Chen, Wenhui Zhu, Baixiang Xiao, Jun Wang, Zhongqiang Zhou, Zhizheng Tang, Yan Liang, Mabel Crescioni, David Wilson, Helen McAneney, Joshua D. Silver, Bruce Moore, Nathan Congdon
Journal: Ophthalmology (2019)
Comparison of long-term survival outcomes of operative versus nonoperative management of recurrent rectal cancer.
Authors: Aneel Bhangu, Mohammed Ali, David Cunningham, Gina Brown, Paris P Tekkis
Journal: Journal of Clinical Oncology (2012)

e14132 Background: Complete surgical resection is considered the best treatment for recurrent rectal cancer (RRC). The aim of the study was to compare survival outcomes from operative and non-operative patients presenting with RRC. Methods: Patients with RRC whose management was discussed by a tertiary referral specialist multidisciplinary team between January 2007 and August 2011 were identified from a prospectively maintained database. The primary endpoint was 5-year overall survival estimated by Kaplan-Meier survival method. Results: Of 127 patients with RRC, 105 were isolated to the pelvis and 22 were associated with distant disease at presentation. From the time of primary surgery to first recurrence, 1, 3, 5 and 10-year local recurrence rates were 22%, 72%, 85% and 96% respectively. Of 70 patients (55%, 70/127) who underwent pelvic resection of recurrence, 64% underwent R0, 20% R1 and 16% R2 resections. Corresponding 5-year overall survival was R0: 60%, R1: 42% and R2: 0% (log-rank p=0.004). There was no significant difference in survival between R2 resection and those managed non-operatively (hazard ratio 0.738, 95% confidence interval 0.341-1.600, p=0.559). Five year disease-free survival was 53% with R0 resection and 30% with R1 resection. Conclusions: Most recurrences occur within 5 years of primary surgery, although some occur up to 10 years later. R0 resection is the treatment of choice that leads to long-term survival and is suitable as an early surrogate marker for long-term survival. There was no survival benefit of R2 resection over non-resected recurrences.
Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma
Authors: Bhishamjit S. Chera, Robert J. Amdur, Rebecca Green, Colette Shen, Gaorav Gupta, Xianming Tan, Mary Knowles, David Fried, Neil Hayes, Jared Weiss, Juneko Grilley-Olson, Shetal Patel, Adam Zanation, Trevor Hackman, Jose Zevallos, Jeffrey Blumberg, Samip Patel, Mohit Kasibhatla, Nathan Sheets, Mark Weissler, Wendell Yarbrough, William Mendenhall
Journal: Journal of Clinical Oncology (2019)

To report the results of a phase II clinical trial of de-intensified chemoradiotherapy for patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
Authors: Jens Ricke, Heinz Josef Klümpen, Holger Amthauer, Irene Bargellini, Peter Bartenstein, Enrico N. de Toni, Antonio Gasbarrini, Maciej Pech, Markus Peck-Radosavljevic, Peter Popovič, Olivier Rosmorduc, Eckart Schott, Max Seidensticker, Chris Verslype, Bruno Sangro, Peter Malfertheiner
Journal: Journal of Hepatology (2019)
A phase II trial of docetaxel, thalidomide, bevacizumab, and prednisone in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)
Authors: Y. M. Ning, P. M. Arlen, J. Gulley, L. Latham, A. Retter, J. Wright, H. Parnes, P. Pinto, W. D. Figg, W. L. Dahut
Journal: Journal of Clinical Oncology (2006)

13037 Background: Angiogenesis plays a vital role in progression of prostate cancer. Antiangiogenic agents’ thalidomide (Td) and bevacizumab (Bv) have been shown in Phase II trials to enhance docetaxel (Doc) activity in metastatic AIPC. Td plus Doc also improved median overall survival as compared to Doc alone. Td and Bv have different antiangiogenic mechanisms. Td appears to affect bFGF, alter circulating endothelial cells and inhibit TNF expression; yet Td does not affect the target of Bv (VEGF). Since tumor angiogenesis is a complex interplay of multiple angiogenic factors, we reasoned that combination of mechanistically different antiangiogenic agents Td and Bv with Doc might be associated with an adequately high and durable PSA response to merit further study. Methods: Pts have progressive, metastatic AIPC, with no prior chemotherapy for AIPC, or prior Td or Bv. Treatment consists of Doc 75 mg/m 2 plus Bv 15 mg/kg day 1, q 21 days as a cycle (C), plus Td 200 mg qhs and prednisone10 mg qd. Enoxaparin 1 mg/kg/d sq is used for thrombosis prevention. PSA is assayed q C and radiographic studies are performed at C 0, C 2, &amp; then q 3 Cs. Results: To date, 22 of planned 60 pts have been enrolled, median age 65 [54–79], Gleason score 8 [Gs 6∼7: 32%, Gs 8∼10: 68%], on-study PSA 111 ng/ml [7.7–4399], &amp; pre-treatment PSA doubling time 1.7 months [0.8–18.2]. I) All 22 pts are actively on trial without progression, with median treatment 6 Cs [1–12]. II) 20 pts treated ≥ 2 Cs, 17 (85%) had PSA declines of &gt;50%, 2 declines of &gt;20%, and 1 stable; median duration of &gt;50% PSA decline is 5 Cs [0∼11]. III) 14 pts (of the 20) treated ≥ 5 Cs, 13 (93%) had &gt;50% PSA declines; 6 of them also had measurable disease: 1 CR, 2 PR, &amp; 3 SD (50% RR). IV) Significant toxicities include grade 4 neutropenia (11/22), grade 3 febrile neutropenia (3/22), syncope (2/22), &amp; colon perforation (1/22). No thrombosis was seen. Conclusions: This trial tests a novel strategy of improving conventional treatment of metastatic AIPC. Our data show that the combination of two mechanistically different antiangiogenic agents Td and Bv with Doc does result in a high durable response in PSA (85∼93%) with acceptable toxicities, suggesting that further studies with the combination are warranted. Accrual is continuing. No significant financial relationships to disclose.
<i>Notes from the Field</i>: Rabies Outbreak Investigation — Pedernales, Dominican Republic, 2019
Authors: Anna Mandra, David Morán, Patricia Valerio Santana, Miguel de la Cruz Marrero, Elina Díaz, Manuel Gil, Rannily Rojas Nolasco, Rinaldy Capellan, Xiomara Acosta, Rafael Pérez, Carmen Céspedes, Bienvenido Báez, Rene Edgar Condori, Todd Smith, James Ellison, Lauren Greenberg, Benjamin Monroe, Andy Gibson, Ryan M. Wallace, Brett Petersen
Journal: MMWR Morbidity and Mortality Weekly Report (2019)
Specific challenge testing for occupational asthma: revised handbook
Authors: Hille Suojalehto, Katri Suuronen, Paul Cullinan
Journal: European Respiratory Journal (2019)

<b>Specific inhalation challenge is considered a reference standard in the diagnosis of occupational asthma. An updated handbook of challenge techniques for a large number of sensitising agents from 11 European centres is now available.</b>http://bit.ly/2XVpW1P